Orgotein (superoxide dismutase): A drug for the amelioration of radiation-induced side effects
- 1 January 1978
- journal article
- clinical trial
- Published by Springer Nature in Urological Research
- Vol. 6 (4) , 255-257
- https://doi.org/10.1007/bf00262630
Abstract
Orgotein, the drug version of Cu-Zn superoxide dismutases is a new and safe anti-inflammatory agent. Animal experiments have shown that it does not interfere with the tumourolytic effects of radiation or chemotherapy. A double-blind, placebo-controlled study has demonstrated that orgotein injected after each daily irradiation session can be used safely and effectively to ameliorate or prevent the side effects due to high-energy radiation therapy (8,400 or 6,400 rads) of bladder tumours. Orgotein significantly reduced the signs and symptoms both in the bladder and the bowel, indicating that it provides a therapeutic regimen for control of these side effects, which to date could only be treated symptomatically.Keywords
This publication has 6 references indexed in Scilit:
- Studies on the clinical and laboratory pharmacology of drug formulations of bovine Cu—Zn superoxide dismutases (orgotein)Published by Springer Nature ,1977
- Orgotein efficacy in ameliorating side effects due to radiation therapy. I. Double-blind, placebo-controlled trial in patients with bladder tumors.1976
- Free radicals and inflammation. Protection of phagocytosine leukocytes by superoxide dismutase.Journal of Clinical Investigation, 1975
- A low dose-fractionation shceme for the radiotherapy of carcinoma of the bladder. Experimental background and preliminary results.1975
- Superoxide DismutasesAnnual Review of Biochemistry, 1975
- Safety tests of orgotein, an antiinflammatory proteinToxicology and Applied Pharmacology, 1973